Bacteroides Probiotics Modulate Gut-Brain Axis for ASD Behavior
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autism spectrum disorder (ASD) and schizophrenia lack effective solutions for improving behavioral symptoms such as anxiety, repetitive behaviors, and communication deficits, particularly in adults with specific gut microbiota signatures.
Innovation Solution
Administration of probiotics comprising Bacteroides bacteria, such as B. fragilis, B. thetaiotaomicron, and B. vulgatus, either alone or in combination with Enterococcus bacteria, to adults with adult gut microbiota signatures, aiming to improve behavioral performance by targeting anxiety, repetitive behaviors, and communication deficits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for ASD and schizophrenia are used, then standard medical care is provided, but behavioral symptoms such as anxiety, repetitive behaviors, and communication deficits are not effectively improved
Solution Approach 1:
The patent introduces probiotics (Bacteroides and Enterococcus bacteria) as an intermediary substance that mediates between the gut microbiota and the central nervous system. These probiotics act as a bridge to modulate the gut-brain axis, thereby improving behavioral symptoms of ASD and schizophrenia without directly targeting the brain, thus resolving the contradiction between providing standard care and achieving behavioral improvement.
Solution Approach 2:
The patent changes the parameter of gut microbiota composition by administering specific probiotic bacteria (Bacteroides fragilis, Bacteroides thetaiotaomicron, Enterococcus faecalis). This parameter change in the microbial ecosystem leads to downstream effects on behavior, transforming the treatment approach from direct neurological intervention to microbiota-mediated modulation.
2Productivity
If probiotics comprising Bacteroides and Enterococcus bacteria are administered, then behavioral performance is improved, but the treatment targets a specific subset of patients with adult gut microbiota signatures
Solution Approach 1:
The patent applies local quality by tailoring the treatment to patients with specific gut microbiota characteristics (adult-like signatures). Rather than a universal approach, the treatment is customized to those who exhibit particular microbial profiles, optimizing effectiveness for the target population while acknowledging limitations for others.
Solution Approach 2:
The patent introduces dynamics by using gut microbiota signature as a variable criterion for treatment selection. The approach adapts to individual patient characteristics, making the treatment dynamic rather than static, where the decision to treat depends on the patient's current microbial state.
3Reliability
If the gut microbiota signature is identified as an adult signature requiring specific probiotics, then targeted treatment is provided, but the complexity of identifying and matching microbiota profiles increases
Solution Approach 1:
The patent uses copying by creating a simplified representation of the complex gut microbiota through a signature profile. Instead of analyzing the entire microbial ecosystem in detail, a condensed signature is generated that captures the essential characteristics needed for treatment matching, reducing complexity while maintaining accuracy.
Solution Approach 2:
The patent extracts the critical information from the complex gut microbiota composition by identifying specific signature characteristics that predict treatment response. This extraction process isolates the most relevant features needed for treatment decision-making, separating essential information from unnecessary complexity.
Data Source
AI summary
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The subject in need thereof can have a gut microbiota signature characteristic of an adult. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiotaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.